BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...

From novel cancer-fighting microRNAs to new types of drug manufacturing facilities, Japan is breaking new ground in clinical research. The complexity of diseases, and the challenges inherent in ...

BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and formulation capabilities with the launch of a GMP-like mRNA manufacturing service, ...

Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...

SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 / EINPresswire.com / -- MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), ...

In today’s fast-paced biopharmaceutical industry, accelerating microbial process development is critical for moving from gene to GMP with greater speed and efficiency. This webinar will highlight ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the ...

All amounts are stated in Canadian Dollars unless otherwise noted VANCOUVER, BC, March 29, 2021 /CNW/ - Artemis Gold Inc. (TSXV: ARTG) ("Artemis" or the "Company") is pleased to announce that after a ...